ÇİLLİ, A. Et Al. 2023. Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions. Respiratory Investigation , vol.61, no.4 , 490-497.

ÇİLLİ, A., Ocal, N., ÜZER, F., COŞKUN, N. F., SEVİNÇ, C., URSAVAŞ, A., ... Yıldız, P.(2023). Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions. Respiratory Investigation , vol.61, no.4, 490-497.

ÇİLLİ, AYKUT Et Al. "Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions," Respiratory Investigation , vol.61, no.4, 490-497, 2023

ÇİLLİ, AYKUT Et Al. "Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions." Respiratory Investigation , vol.61, no.4, pp.490-497, 2023

ÇİLLİ, A. Et Al. (2023) . "Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions." Respiratory Investigation , vol.61, no.4, pp.490-497.

@article{article, author={AYKUT ÇİLLİ Et Al. }, title={Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions}, journal={Respiratory Investigation}, year=2023, pages={490-497} }